Table 2. Open in new tab Comparison of...

Patients with MH

Patients without MH

OR (95% CI)

Age, y

37 ± 9.9

39 ± 7.42

0.98 (0.96-1.09)

.18

Male

63.64 (21/33)

40.74 (11/27)

2.54 (0.86-7.51)

.07

Body mass index, kg/m²

24.94 ± 3.29

22.2 ± 3.2

1.24 (1.08-1.44)

.01

UC extension

18.18 (6/33)

44.4 (12/27)

0.28 (0.08-0.94)

.02

21.21 (7/33)

33.3 (9/27)

0.53 (0.16-1.74)

.29

60.61 (20/33)

22.2 (6/27)

5.38 (1.54-18.81)

.003

Time from UC diagnosis, y

9.91 ± 8.97

8 ± 4.93

1.03 (0.96-1.11)

.16

UC medication use

Mesalamine

81.82 (27/33)

62.96 (17/27)

2.64 (0.78-8.94)

Thiopurines

27.27 (9/33)

29.63 (8/27)

0.89 (0.28-2.77)

.84

Systemic steroids

12.12 (4/33)

14.81 (4/27)

0.79 (0.17-3.56)

.76

Anti-TNF

18.18 (6/33)

7.41 (2/27)

2.77 (0.49-15.61)

.22

Ustekinumab

12.12 (4/33)

7.41 (2/27)

1.72 (0.28-10.43)

.54

Vedolizumab

3.03 (1/33)

N/A

.09

No active treatment

22.22 (6/27)

N/A

.004

Statins

6.06 (2/33)

N/A

.19

ACE inhibitors

6.06 (2/33)

7.41 (2/27)

0.8 (0.1-6.24)

.83

Dyslipidemia

6.06 (2/33)

7.41 (2/27)

0.8 (0.1-6.24)

.83

Hypertension

6.06 (2/33)

7.41 (2/27)

0.8 (0.1-6.24)

.83

Total Cholesterol, mg/dL

208.32 ± 27.5

202.1 ± 24.32

1.02 (0.98-1.07)

.08

HDL, mg/dL

63.26 ± 19.1

51.43 ± 9.2

1.04 (1.01-1.08)

.006

LDL, mg/dL

118.48 ± 19.82

121 ± 32.87

0.99 (0.97-1.02)

.38

Triglycerides, mg/dL

114.52 ± 46.59

95.04 ± 40.16

1 (0.99-1.02)

.07

C-reactive protein, mg/dL

0.28 ± 0.28

0.79 ± 0.64

0.15 (0.05-0.43)

.001

Hemoglobin, g/dL

14.08 ± 1.75

13.89 ± 0.7

1.1 (0.74-1.62)

.31

Vitamin D, UI/mL

28.6 ± 13.32

26.56 ± 6.31

1.01 (0.94-1.09)

.28

Table 2.

Open in new tab

Comparison of UC patients with and without MH

	Patients with MH	Patients without MH	OR (95% CI)	P
Age, y	37 ± 9.9	39 ± 7.42	0.98 (0.96-1.09)	.18
Male	63.64 (21/33)	40.74 (11/27)	2.54 (0.86-7.51)	.07
Body mass index, kg/m²	24.94 ± 3.29	22.2 ± 3.2	1.24 (1.08-1.44)	.01
UC extension
E1	18.18 (6/33)	44.4 (12/27)	0.28 (0.08-0.94)	.02
E2	21.21 (7/33)	33.3 (9/27)	0.53 (0.16-1.74)	.29
E3	60.61 (20/33)	22.2 (6/27)	5.38 (1.54-18.81)	.003
Time from UC diagnosis, y	9.91 ± 8.97	8 ± 4.93	1.03 (0.96-1.11)	.16
UC medication use
Mesalamine	81.82 (27/33)	62.96 (17/27)	2.64 (0.78-8.94)	.1
Thiopurines	27.27 (9/33)	29.63 (8/27)	0.89 (0.28-2.77)	.84
Systemic steroids	12.12 (4/33)	14.81 (4/27)	0.79 (0.17-3.56)	.76
Anti-TNF	18.18 (6/33)	7.41 (2/27)	2.77 (0.49-15.61)	.22
Ustekinumab	12.12 (4/33)	7.41 (2/27)	1.72 (0.28-10.43)	.54
Vedolizumab	3.03 (1/33)	0	N/A	.09
No active treatment	0	22.22 (6/27)	N/A	.004
Statins	6.06 (2/33)	0	N/A	.19
ACE inhibitors	6.06 (2/33)	7.41 (2/27)	0.8 (0.1-6.24)	.83
Dyslipidemia	6.06 (2/33)	7.41 (2/27)	0.8 (0.1-6.24)	.83
Hypertension	6.06 (2/33)	7.41 (2/27)	0.8 (0.1-6.24)	.83
Total Cholesterol, mg/dL	208.32 ± 27.5	202.1 ± 24.32	1.02 (0.98-1.07)	.08
HDL, mg/dL	63.26 ± 19.1	51.43 ± 9.2	1.04 (1.01-1.08)	.006
LDL, mg/dL	118.48 ± 19.82	121 ± 32.87	0.99 (0.97-1.02)	.38
Triglycerides, mg/dL	114.52 ± 46.59	95.04 ± 40.16	1 (0.99-1.02)	.07
C-reactive protein, mg/dL	0.28 ± 0.28	0.79 ± 0.64	0.15 (0.05-0.43)	.001
Hemoglobin, g/dL	14.08 ± 1.75	13.89 ± 0.7	1.1 (0.74-1.62)	.31
Vitamin D, UI/mL	28.6 ± 13.32	26.56 ± 6.31	1.01 (0.94-1.09)	.28

	Patients with MH	Patients without MH	OR (95% CI)	P
Age, y	37 ± 9.9	39 ± 7.42	0.98 (0.96-1.09)	.18
Male	63.64 (21/33)	40.74 (11/27)	2.54 (0.86-7.51)	.07
Body mass index, kg/m²	24.94 ± 3.29	22.2 ± 3.2	1.24 (1.08-1.44)	.01
UC extension
E1	18.18 (6/33)	44.4 (12/27)	0.28 (0.08-0.94)	.02
E2	21.21 (7/33)	33.3 (9/27)	0.53 (0.16-1.74)	.29
E3	60.61 (20/33)	22.2 (6/27)	5.38 (1.54-18.81)	.003
Time from UC diagnosis, y	9.91 ± 8.97	8 ± 4.93	1.03 (0.96-1.11)	.16
UC medication use
Mesalamine	81.82 (27/33)	62.96 (17/27)	2.64 (0.78-8.94)	.1
Thiopurines	27.27 (9/33)	29.63 (8/27)	0.89 (0.28-2.77)	.84
Systemic steroids	12.12 (4/33)	14.81 (4/27)	0.79 (0.17-3.56)	.76
Anti-TNF	18.18 (6/33)	7.41 (2/27)	2.77 (0.49-15.61)	.22
Ustekinumab	12.12 (4/33)	7.41 (2/27)	1.72 (0.28-10.43)	.54
Vedolizumab	3.03 (1/33)	0	N/A	.09
No active treatment	0	22.22 (6/27)	N/A	.004
Statins	6.06 (2/33)	0	N/A	.19
ACE inhibitors	6.06 (2/33)	7.41 (2/27)	0.8 (0.1-6.24)	.83
Dyslipidemia	6.06 (2/33)	7.41 (2/27)	0.8 (0.1-6.24)	.83
Hypertension	6.06 (2/33)	7.41 (2/27)	0.8 (0.1-6.24)	.83
Total Cholesterol, mg/dL	208.32 ± 27.5	202.1 ± 24.32	1.02 (0.98-1.07)	.08
HDL, mg/dL	63.26 ± 19.1	51.43 ± 9.2	1.04 (1.01-1.08)	.006
LDL, mg/dL	118.48 ± 19.82	121 ± 32.87	0.99 (0.97-1.02)	.38
Triglycerides, mg/dL	114.52 ± 46.59	95.04 ± 40.16	1 (0.99-1.02)	.07
C-reactive protein, mg/dL	0.28 ± 0.28	0.79 ± 0.64	0.15 (0.05-0.43)	.001
Hemoglobin, g/dL	14.08 ± 1.75	13.89 ± 0.7	1.1 (0.74-1.62)	.31
Vitamin D, UI/mL	28.6 ± 13.32	26.56 ± 6.31	1.01 (0.94-1.09)	.28

Values are mean ± SD or % (n/n).

Abbreviations: ACE, angiotensin-converting enzyme; CI, confidence interval; HDL, high-density lipoprotein; IMT, intima-media thickness; LDL, low-density lipoprotein; MH, mucosal healing; N/A, non-applicable; OR, odds ratio; TNF, tumor necrosis factor; UC, ulcerative colitis.

This Feature Is Available To Subscribers Only